Contact
searchSearch
HMP Global
Login

Renal Cell Carcinoma Specialty Channel

Andrew Hahn, MD
Videos
Lenvatinib Plus Everolimus Extends PFS for Patients With Metastatic Clear Cell Renal Cell Carcinoma
10/19/2025
Andrew Hahn, MD
Andrew Hahn, MD, discusses results from the phase 2 LenCabo trial comparing lenvatinib plus everolimus with cabozantinib in patients with metastatic clear cell renal cell carcinoma who experienced disease progression after PD-1–based therapy.
Andrew Hahn, MD, discusses results from the phase 2 LenCabo trial comparing lenvatinib plus everolimus with cabozantinib in patients with metastatic clear cell renal cell carcinoma who experienced disease progression after PD-1–based therapy.
Andrew Hahn, MD, discusses...
10/19/2025
Oncology
News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
Conference Coverage
Long-Term Benefit of Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
02/13/2025
Allison Casey
According to the long-term data from the phase 3 CheckMate 9ER trial, nivolumab plus cabozantinib continued to show an efficacy benefit, compared with sunitinib among untreated patients with advanced renal cell carcinoma.
According to the long-term data from the phase 3 CheckMate 9ER trial, nivolumab plus cabozantinib continued to show an efficacy benefit, compared with sunitinib among untreated patients with advanced renal cell carcinoma.
According to the long-term data...
02/13/2025
Oncology
Conference Coverage
First-Line Cabozantinib Plus Nivolumab and Ipilimumab for Advanced Renal Cell Carcinoma
02/13/2025
Allison Casey
In the phase 3 COSMIC-313 trial, final results indicated that cabozantinib plus nivolumab and ipilimumab maintained its PFS benefit with comparable OS when compared with placebo plus nivolumab and ipilimumab among patients with intermediate...
In the phase 3 COSMIC-313 trial, final results indicated that cabozantinib plus nivolumab and ipilimumab maintained its PFS benefit with comparable OS when compared with placebo plus nivolumab and ipilimumab among patients with intermediate...
In the phase 3 COSMIC-313 trial,...
02/13/2025
Oncology
Conference Coverage
First-Line Lenvatinib Plus Tislelizumab Demonstrates Promise for Patients With Fumarate Hydratase-Deficient Renal Cell Carcinoma
02/13/2025
Stephanie Holland
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results...
02/13/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Stephanie Holland
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma
08/30/2024
Stephanie Holland
According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...
According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...
According to results from the...
08/30/2024
Oncology
News
Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the...
04/25/2024
Oncology
News
Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis...
04/25/2024
Oncology
News
Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence
04/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the...
04/16/2024
Oncology
Quiz
Belzutifan vs Everolimus for Quality of Life of Patients With Advanced Clear Cell Renal Cell Carcinoma
03/21/2024
Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?
Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?
Did belzutifan improve the time...
03/21/2024
Oncology

News

News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
Conference Coverage
Long-Term Benefit of Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
02/13/2025
Allison Casey
According to the long-term data from the phase 3 CheckMate 9ER trial, nivolumab plus cabozantinib continued to show an efficacy benefit, compared with sunitinib among untreated patients with advanced renal cell carcinoma.
According to the long-term data from the phase 3 CheckMate 9ER trial, nivolumab plus cabozantinib continued to show an efficacy benefit, compared with sunitinib among untreated patients with advanced renal cell carcinoma.
According to the long-term data...
02/13/2025
Oncology
Conference Coverage
First-Line Cabozantinib Plus Nivolumab and Ipilimumab for Advanced Renal Cell Carcinoma
02/13/2025
Allison Casey
In the phase 3 COSMIC-313 trial, final results indicated that cabozantinib plus nivolumab and ipilimumab maintained its PFS benefit with comparable OS when compared with placebo plus nivolumab and ipilimumab among patients with intermediate...
In the phase 3 COSMIC-313 trial, final results indicated that cabozantinib plus nivolumab and ipilimumab maintained its PFS benefit with comparable OS when compared with placebo plus nivolumab and ipilimumab among patients with intermediate...
In the phase 3 COSMIC-313 trial,...
02/13/2025
Oncology
Conference Coverage
First-Line Lenvatinib Plus Tislelizumab Demonstrates Promise for Patients With Fumarate Hydratase-Deficient Renal Cell Carcinoma
02/13/2025
Stephanie Holland
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results...
02/13/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Stephanie Holland
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma
08/30/2024
Stephanie Holland
According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...
According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...
According to results from the...
08/30/2024
Oncology
News
Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the...
04/25/2024
Oncology
News
Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis...
04/25/2024
Oncology
News
Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence
04/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the...
04/16/2024
Oncology
News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology

Interactive Features

Quiz
Belzutifan vs Everolimus for Quality of Life of Patients With Advanced Clear Cell Renal Cell Carcinoma
03/21/2024
Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?
Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?
Did belzutifan improve the time...
03/21/2024
Oncology
Quiz
Quiz: Post-Surgery Everolimus for High-Risk Renal Cell Carcinoma
09/02/2022
In the phase 3 EVEREST trial which looked at everolimus after surgery in patients with high-risk renal cancer, which patients saw the greatest benefit in recurrence-free survival with everolimus?
In the phase 3 EVEREST trial which looked at everolimus after surgery in patients with high-risk renal cancer, which patients saw the greatest benefit in recurrence-free survival with everolimus?
In the phase 3 EVEREST trial...
09/02/2022
Oncology
Test Your Knowledge
Quiz: Which Study Yields Notable Benefit in Kidney Cancer?
04/15/2021
Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk groups and regardless of PD‑L1 expression...
Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk groups and regardless of PD‑L1 expression...
Which study reported OS results...
04/15/2021
Oncology
Test Your Knowledge
Quiz: Which Combo Regimen Received FDA Approval for Treatment of Advanced RCC?
02/02/2021
Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?
Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?
Which combo therapy regimen was...
02/02/2021
Oncology
Test Your Knowledge
Quiz: Which Therapy Had Higher Safety, OS in Papillary RCC?
10/13/2020
Which therapy had a better safety profile and OS rate in the SAVOIR trial for papillary RCC?
Which therapy had a better safety profile and OS rate in the SAVOIR trial for papillary RCC?
Which therapy had a better...
10/13/2020
Oncology
Test Your Knowledge
Quiz: Is Pembrolizumab Plus Bevacizumab Beneficial for Metastatic RCC?
09/02/2020
True or False: Pembrolizumab combined with bevacizumab was proven safe and active in a study of patients with metastatic clear cell renal cell carcinoma.
True or False: Pembrolizumab combined with bevacizumab was proven safe and active in a study of patients with metastatic clear cell renal cell carcinoma.
True or False: Pembrolizumab...
09/02/2020
Oncology
Test Your Knowledge
Quiz: Is Ipilimumab Plus Nivolumab Active in Patients with Metastatic RCC?
07/31/2020
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus...
07/31/2020
Oncology
Test Your Knowledge
Quiz: Does Nivolumab–Ipilimumab Yield Long-Term Benefit in Advanced RCC?
10/01/2019
True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.
True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.
True or False: Combining...
10/01/2019
Oncology

Recent News

News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
Conference Coverage
First-Line Lenvatinib Plus Tislelizumab Demonstrates Promise for Patients With Fumarate Hydratase-Deficient Renal Cell Carcinoma
02/13/2025
Stephanie Holland
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results...
02/13/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Stephanie Holland
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma
08/30/2024
Stephanie Holland
According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...
According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...
According to results from the...
08/30/2024
Oncology
News
Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the...
04/25/2024
Oncology
News
Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis...
04/25/2024
Oncology
News
Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence
04/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the...
04/16/2024
Oncology
News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
News
Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective...
03/11/2024
Oncology
News
Belzutifan Plus Cabozantinib Shows Promise in Previously Treated Clear Cell Renal Cell Carcinoma
04/12/2023
In a phase 2 trial, belzutifan plus cabozantinib showed promising antitumor activity among patients with clear cell renal cell carcinoma who had received prior PD-1/PD-L1 inhibition.
In a phase 2 trial, belzutifan plus cabozantinib showed promising antitumor activity among patients with clear cell renal cell carcinoma who had received prior PD-1/PD-L1 inhibition.
In a phase 2 trial, belzutifan...
04/12/2023
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use